ALNYLAM PHARMACEUTICALS, INC. 8-K

What Happened
On January 11, 2026, Alnylam Pharmaceuticals announced a new five‑year strategy called "Alnylam 2030" and reported preliminary, unaudited fourth‑quarter and full‑year 2025 net product revenues. The company said Q4 2025 net product revenue was approximately $995 million and full‑year 2025 net product revenue was approximately $2,987 million for its marketed RNAi medicines AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran) and OXLUMO (lumasiran). Alnylam also provided product and pipeline goals for 2026 and announced full‑year 2026 combined net product revenue guidance. The preliminary figures are unaudited, subject to adjustment, and final results will be released in February 2026.

Key Details

• Date of announcement: January 11, 2026.
• Preliminary Q4 2025 net product revenue: ≈ $995 million.
• Preliminary full‑year 2025 net product revenue: ≈ $2,987 million (combined for AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO).
• Results are preliminary and unaudited; complete financial results and formal earnings release expected in February 2026.
• Company announced full‑year 2026 combined net product revenue guidance (amount to be disclosed in the complete results).

Why It Matters
These preliminary revenue figures give investors an early look at Alnylam’s commercial performance and scale as it approaches $3.0 billion in product revenue for 2025, which is a key indicator of adoption for its marketed RNAi therapies. The new "Alnylam 2030" strategy signals the company’s multi‑year priorities for R&D, commercialization and growth. Because the numbers are unaudited and subject to adjustment, investors should wait for the full, audited results and formal guidance details in February 2026 before making decisions based on these preliminary earnings and revenue figures.